Payer Almanac
About the data Sign in
Star measuresDisplay measuresHEDISWhy members leave

Display measures

Measures CMS publishes alongside the Star Ratings but doesn't score: new measures being tested before they count, measures retired from the Star Ratings, and operational ones such as call-center hold times and grievance rates. Published with the 2026 Star Ratings; most measure 2024. CMS posts each year's display measures a few weeks after the ratings.

How to read this

National average: CMS's published average for MA contracts (and for stand-alone drug plans where CMS gives one), from the Display Measures Technical Notes. Better: which direction is good; display measures have no stars, so this site sets it from what each measure counts (a lower grievance rate, a higher screening rate). Two measures have no better direction: Plan Finder price stability, where 100% means prices held steady, and plans' submitted prices.

A measure followed across years is matched by name, because CMS renumbers display measures most years. Hold times are minutes:seconds.

Customer service and complaints

MeasureNational averageMA · drug plansPrior yearMABetterContracts reportingYears published
Call Center – Beneficiary Hold Time (health plan)DMC04 0:32 0:37 Lower 703 11since 2016
Call Center - Calls Disconnected When Customer Calls Health PlanDMC07 1% 1.4% Lower 703 11since 2016
Call Center - Calls Disconnected When Customer Calls Drug PlanDMD01 0.9%0.8% 1.4% Lower 721 11since 2016
Call Center – Beneficiary Hold Time (drug plan)DMD02 0:300:36 0:35 Lower 721 11since 2016
Call Center – Pharmacy Hold TimeDMD04 0:200:17 0:27 Lower 721 11since 2016
Grievance RateDME01 7.211.54 6.73 Lower 578 12since 2015
Beneficiary Access and Performance ProblemsDME07 9495 90 Higher 749 9since 2015

Why members leave

Hospital stays and care transitions

MeasureNational averageMA · drug plansPrior yearMABetterContracts reportingYears published
Follow-up Visit after Hospital Stay for Mental Illness (within 30 days of discharge)DMC01 51% 50% Higher 363 12since 2015
Hospitalization for Potentially Preventable ComplicationsDMC13 37% 18% Lower 552 10since 2017
Transitions of Care - Medication Reconciliation Post-DischargeDMC14 77% 72% Higher 587 7since 2020
Transitions of Care - Notification of Inpatient AdmissionDMC15 52% 45% Higher 584 7since 2020
Transitions of Care - Patient Engagement After Inpatient DischargeDMC16 88% 86% Higher 587 7since 2020
Transitions of Care - Receipt of Discharge InformationDMC17 34% 29% Higher 584 7since 2020

Prevention and chronic care

MeasureNational averageMA · drug plansPrior yearMABetterContracts reportingYears published
Continuous Beta Blocker TreatmentDMC02 72% 72% Higher 141 12since 2015
Pneumonia VaccineDMC05 68% 68% Higher 544 12since 2015
Pharmacotherapy Management of COPD Exacerbation – Systemic CorticosteroidDMC08 75% 74% Higher 466 12since 2015
Pharmacotherapy Management of COPD Exacerbation – BronchodilatorDMC09 84% 84% Higher 466 12since 2015
Initiation of Substance Use Disorder TreatmentDMC10 35% 35% Higher 516 3since 2024
Engagement of Substance Use Disorder TreatmentDMC11 5% 5% Higher 516 3since 2024
Initiation and Engagement of Substance Use Disorder Treatment Average DMC12DMC12 20% 20% Higher 516 3since 2024
Cardiac Rehabiliation - AcheivementDMC20 5% 4% Higher 417 4since 2023
Cardiac Rehabiliation - Engagement 1DMC21 11% 11% Higher 417 4since 2023
Cardiac Rehabiliation - Engagement 2DMC22 10% 10% Higher 417 4since 2023
Cardiac Rehabilation - InitiationDMC23 8% 8% Higher 417 4since 2023
Colorectal Cancer Screening (Age 45-75)DMC24 70% 71% Higher 609 3since 2024
Adult Immunization Status - InfluenzaDMC25 39% — Higher 621 1since 2026
Adult Immunization Status - PneumococcalDMC26 52% — Higher 618 1since 2026
Adult Immunization Status - Td/TdapDMC27 32% — Higher 621 1since 2026
Adult Immunization Status - ZosterDMC28 22% — Higher 621 1since 2026
Adult Immunization Status - AverageDMC29 36% — Higher 618 1since 2026
Depression Screening and Follow-Up - Depression ScreeningDMC30 16% — Higher 621 1since 2026
Depression Screening and Follow-Up - Follow-Up on Positive ScreenDMC31 69% — Higher 260 1since 2026
Depression Screening and Follow-Up - AverageDMC32 47% — Higher 260 1since 2026

Member experience and functioning

MeasureNational averageMA · drug plansPrior yearMABetterContracts reportingYears published
Doctors who Communicate WellDMC03 93% 93% Higher 315 12since 2015
Access to Primary Care Doctor VisitsDMC06 95% 95% Higher 621 12since 2015
Physical Functioning Activities of Daily LivingDMC18 94% 94% Higher 493 6since 2021
Care of Older Adults - Functional StatusDMC19 84% 80% Higher 344 5since 2022

Prescriptions and drug plan

MeasureNational averageMA · drug plansPrior yearMABetterContracts reportingYears published
MPF – StabilityDMD03 100%100% 100% — 649 12since 2015
Plan Submitted Higher Prices for Display on MPFDMD05 5756 74 — 693 12since 2015
Reminders to Fill PrescriptionsDMD06 55%53% 55% Higher 574 12since 2015
Reminders to Take MedicationsDMD07 35%27% 34% Higher 576 12since 2015
Persistence to Basal Insulin (PST-INS)DMD16 70%69% 70% Higher 651 3since 2024
Medication Adherence for Diabetes Medications Measure with Risk Adjustment (RA)DMD17 87%86% — Higher 694 1since 2026
Medication Adherence for Hypertension (RAS Antagonists) Measure with RA (ADH-RAS RA)DMD18 90%88% — Higher 708 1since 2026
Medication Adherence for Cholesterol (Statins) Measure with RA (ADH-Statins RA)DMD19 88%87% — Higher 712 1since 2026

Drug safety

MeasureNational averageMA · drug plansPrior yearMABetterContracts reportingYears published
Antipsychotic Use in Persons with DementiaDMD08 8%9% 7% Lower 652 9since 2018
Antipsychotic Use in Persons with Dementia - for Long-Term Nursing Home ResidentsDMD09 — 7% Lower 398 8since 2019
Concurrent Use of Opioids and BenzodiazepinesDMD10 13%14% 14% Lower 655 6since 2021
Use of Opioids at High Dosage in Persons Without CancerDMD11 5%5% 6% Lower 657 6since 2021
Use of Opioids from Multiple Providers in Persons Without CancerDMD12 0.3%0.2% — Lower 657 6since 2021
Polypharmacy: Use of Multiple Anticholinergic Medications in Older AdultsDMD13 9%7% 9% Lower 659 6since 2021
Polypharmacy: Use of Multiple CNS-Active Medications in Older AdultsDMD14 13%10% 13% Lower 689 6since 2021
Initial Opioid Prescribing (IOP-LD)DMD15 17%12% 17% Lower 680 4since 2023